HRP20120856T1 - Transmukozni veterinarski pripravak koji sadrži detomidin - Google Patents
Transmukozni veterinarski pripravak koji sadrži detomidin Download PDFInfo
- Publication number
- HRP20120856T1 HRP20120856T1 HRP20120856TT HRP20120856T HRP20120856T1 HR P20120856 T1 HRP20120856 T1 HR P20120856T1 HR P20120856T T HRP20120856T T HR P20120856TT HR P20120856 T HRP20120856 T HR P20120856T HR P20120856 T1 HRP20120856 T1 HR P20120856T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation according
- pharmaceutical preparation
- range
- preparation
- relation
- Prior art date
Links
- JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 title claims 2
- 229960001894 detomidine Drugs 0.000 title claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 9
- 239000003349 gelling agent Substances 0.000 claims 6
- 229920002125 Sokalan® Polymers 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 229960001631 carbomer Drugs 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000006184 cosolvent Substances 0.000 claims 3
- 210000004877 mucosa Anatomy 0.000 claims 3
- 230000035515 penetration Effects 0.000 claims 3
- 241000283690 Bos taurus Species 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- -1 polyoxyethylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Claims (23)
1. Farmaceutski veterinarski pripravak u obliku transmukoznog gela, naznačen time, da sadrži, u odnosu na ukupnu masu pripravka, 0,1 - 5 % (w/w) detomidina ili njegove farmaceutski prihvatljive soli; 0,3 - 40 % (w/w) sredstva za geliranje; 0,2 - 15 % (w/w) sredstva za poboljšanje transmukozne penetracije; 5 - 50 % (w/w) organskog kootapala koje se miješa s vodom; te 30 - 80 % (w/w) vode.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je organsko kootapalo koje se miješa s vodom glikol ili C2-C4 alkohol.
3. Farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačen time, da je organsko kootapalo koje se miješa s vodom propilen glikol.
4. Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time, da je udjel propilen glikola u rasponu od 10 do 45% (w/w) u odnosu na ukupnu masu pripravka.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time, da je udjel propilen glikola u rasponu od 15 to 40% (w/w) u odnosu na ukupnu masu pripravka.
6. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je sredstvo za geliranje odabrano između derivata celuloze, poliakrilnih kiselina i kopolimera polioksietilena/polioksipropilena.
7. Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time, da je sredstvo za geliranje hidroksipropil celuloza ili hidroksietil celuloza.
8. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time, da je udjel sredstva za geliranje u rasponu od 0,5 do 40 % u odnosu na ukupnu masu pripravka.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time, da je udjel sredstva za geliranje u rasponu od 1 do 30 % (w/w) u odnosu na ukupnu masu pripravka.
10. Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time, da je sredstvo za geliranje karbomer.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time, da je udjel karbomera u rasponu od 0,3 do 5,0 % (w/w) u odnosu na ukupnu masu pripravka.
12. Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time, da je udjel karbomera u rasponu od 0,5 do 3,0 % (w/w), u odnosu na ukupnu masu pripravka.
13. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je sredstvo za poboljšanje transmukozne penetracije masna kiselina s 5 do 30 atoma ugljika, sulfatna sol masne kiseline s 5 do 30 atoma ugljika ili DMSO.
14. Farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačen time, da je udjel sredstva za poboljšanje transmukozne penetracije u rasponu od 0,5 do 10 % (w/w) u odnosu na ukupnu masu pripravka.
15. Farmaceutski pripravak u skladu s patentnim zahtjevom 13 ili 14, naznačen time, da je sredstvo za poboljšanje transmukozne penetracije natrijev lauril sulfat.
16. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da mu je pH vrijednost u rasponu od 5 do 7.
17. Farmaceutski pripravak u skladu s patentnim zahtjevom 16, naznačen time, da mu je pH vrijednost u rasponu od 5,5 do 6,5.
18. Veterinarski pribor, naznačen time, da sadrži pripravak u skladu s patentnim zahtjevom 1, spremnik koji sadrži navedeni pripravak te upute za davanje navedenog pripravka u mukozu životinje.
19. Pribor u skladu s patentnim zahtjevom 18, naznačen time, da je spremnik u obliku štrcaljke.
20. Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je namijenjen za davanje u mukozu životinje.
21. Pripravak u skladu s patentnim zahtjevom 20, naznačen time, da je navedena mukoza oralna mukoza.
22. Pripravak u skladu s patentnim zahtjevom 20 ili 21, naznačen time, da je namijenjen za uspavljivanje ili obuzdavanje konja, ponija ili goveda ili za postizanje analgetičkog ili anksiolitičkog učinka kod konja, ponija ili goveda.
23. Pripravak u skladu s patentnim zahtjevom 20, naznačen time, da se pripravak (u obujmu od 1 do 10 ml) daje liječenoj životinji sublingvalno iz unaprijed napunjene štrcaljke.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62512904P | 2004-11-05 | 2004-11-05 | |
| FI20041425A FI20041425A0 (fi) | 2004-11-05 | 2004-11-05 | Transmukosaalinen veterinäärinen koostumus |
| PCT/FI2005/000470 WO2006048501A1 (en) | 2004-11-05 | 2005-11-03 | A transmucosal veterinary composition comprising detomidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120856T1 true HRP20120856T1 (hr) | 2012-11-30 |
Family
ID=33515193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120856TT HRP20120856T1 (hr) | 2004-11-05 | 2012-10-23 | Transmukozni veterinarski pripravak koji sadrži detomidin |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7863311B2 (hr) |
| EP (1) | EP1811995B1 (hr) |
| JP (1) | JP4996472B2 (hr) |
| KR (1) | KR101257672B1 (hr) |
| AR (1) | AR054987A1 (hr) |
| AU (1) | AU2005300451B2 (hr) |
| BR (1) | BRPI0517719B1 (hr) |
| CA (1) | CA2583876C (hr) |
| DK (1) | DK1811995T3 (hr) |
| ES (1) | ES2388442T3 (hr) |
| FI (1) | FI20041425A0 (hr) |
| HR (1) | HRP20120856T1 (hr) |
| IL (1) | IL182541A (hr) |
| MX (1) | MX2007005238A (hr) |
| NO (1) | NO338158B1 (hr) |
| NZ (1) | NZ554521A (hr) |
| PL (1) | PL1811995T3 (hr) |
| PT (1) | PT1811995E (hr) |
| RS (1) | RS52504B (hr) |
| SI (1) | SI1811995T1 (hr) |
| WO (1) | WO2006048501A1 (hr) |
| ZA (1) | ZA200703486B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100784134B1 (ko) | 2006-10-09 | 2007-12-12 | 주식회사 대웅 | 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물 |
| ES2393814T3 (es) * | 2007-04-04 | 2012-12-28 | Sigmoid Pharma Limited | Una composición farmacéutica oral |
| US20090246256A1 (en) * | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Compositions and Methods for Transmucosal Delivery of Lofexidine |
| KR101517415B1 (ko) | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| KR20120060833A (ko) * | 2009-09-04 | 2012-06-12 | 가부시키가이샤 시세이도 | Ｏ／ｗ 유화 조성물의 제조 방법 |
| WO2012106058A2 (en) | 2011-01-31 | 2012-08-09 | New Market Pharmaceuticals | Animal treatments |
| US10064849B2 (en) | 2012-05-02 | 2018-09-04 | New Market Pharmaceuticals | Pharmaceutical compositions for direct systemic introduction |
| EP3791866A1 (en) | 2012-05-02 | 2021-03-17 | NewMarket Pharmaceuticals LLC | Pharmaceutical compositions for direct systemic introduction |
| FR2990134B1 (fr) * | 2012-05-07 | 2014-11-21 | Anaconda Pharma | Composition pharmaceutique d'un inhibiteur du virus du papillome |
| BR112015008459B1 (pt) * | 2012-10-15 | 2020-11-10 | Orion Corporation | uso de dexmedetomidina, medetomidina ou um sal farmaceuticamente aceitável destas para a fabricação de um medicamento para aliviar a aversão ao ruído em um animal |
| KR20150111919A (ko) * | 2012-12-21 | 2015-10-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트의 경구 경점막 전달 |
| FI127534B (en) * | 2014-11-10 | 2018-08-31 | Vetcare Oy | Substituted benzoefuroquinolizine and ɑ2-adrenergic agonist comprising compositions |
| JP2020505322A (ja) * | 2017-01-06 | 2020-02-20 | クレキシオ バイオサイエンシーズ エルティーディー． | 局所用デトミジン製剤 |
| WO2020012415A2 (en) * | 2018-07-11 | 2020-01-16 | Clexio Biosciences Ltd. | Topical detomidine formulations |
| JP7534795B2 (ja) | 2019-05-01 | 2024-08-15 | クレキシオ バイオサイエンシーズ エルティーディー． | そう痒症を治療する方法 |
| CN114007617A (zh) * | 2019-05-31 | 2022-02-01 | 葡瑞慕生物技术有限公司 | 用于经黏膜给药药物活性成分的单位剂型 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| FI844786A0 (fi) * | 1984-12-04 | 1984-12-04 | Farmos Oy | Terapeutiskt utnyttjbar foerening. |
| US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| GB2256135B (en) | 1991-05-31 | 1995-01-18 | Orion Yhtymae Oy | Transdermal administration of 4-substituted imidazoles |
| MX9304075A (es) * | 1992-07-08 | 1994-04-29 | Applied Research Systems | Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos. |
| CN1106259A (zh) | 1994-02-05 | 1995-08-09 | 日东制药株式会社 | 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂 |
| JP2001517493A (ja) * | 1997-09-26 | 2001-10-09 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | 生体接着剤組成物及び活性薬剤の局所投与方法 |
| US7001609B1 (en) * | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
| ATE273698T1 (de) * | 1998-10-02 | 2004-09-15 | 3M Innovative Properties Co | Systeme zur arzneistoffabgabe an schleimhäute |
| AU8206401A (en) | 2000-08-03 | 2002-02-18 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| JP4493203B2 (ja) | 2000-12-12 | 2010-06-30 | 株式会社ブリヂストン | 空気入りタイヤの製造方法 |
| DE10107659B4 (de) * | 2001-02-19 | 2008-03-13 | Lts Lohmann Therapie-Systeme Ag | Mucoadhäsive zerfallsfähige Arzneizubereitung zur Wirkstoffverabreichung in der Veterinär- und Humanmedizin |
| DE10256774A1 (de) * | 2002-12-05 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Transmucosale und transdermale Arzneimittel mit verbesserter Wirkstoffresorption |
-
2004
- 2004-11-05 FI FI20041425A patent/FI20041425A0/fi not_active Application Discontinuation
-
2005
- 2005-11-03 RS RS20120440A patent/RS52504B/en unknown
- 2005-11-03 PL PL05804165T patent/PL1811995T3/pl unknown
- 2005-11-03 NZ NZ554521A patent/NZ554521A/en unknown
- 2005-11-03 PT PT05804165T patent/PT1811995E/pt unknown
- 2005-11-03 US US11/667,100 patent/US7863311B2/en active Active
- 2005-11-03 WO PCT/FI2005/000470 patent/WO2006048501A1/en active Application Filing
- 2005-11-03 MX MX2007005238A patent/MX2007005238A/es active IP Right Grant
- 2005-11-03 ES ES05804165T patent/ES2388442T3/es active Active
- 2005-11-03 BR BRPI0517719A patent/BRPI0517719B1/pt active IP Right Grant
- 2005-11-03 EP EP05804165A patent/EP1811995B1/en active Active
- 2005-11-03 CA CA2583876A patent/CA2583876C/en active Active
- 2005-11-03 AU AU2005300451A patent/AU2005300451B2/en active Active
- 2005-11-03 JP JP2007539597A patent/JP4996472B2/ja active Active
- 2005-11-03 SI SI200531588T patent/SI1811995T1/sl unknown
- 2005-11-03 KR KR1020077009256A patent/KR101257672B1/ko active IP Right Grant
- 2005-11-03 DK DK05804165.8T patent/DK1811995T3/da active
- 2005-11-04 AR ARP050104652A patent/AR054987A1/es not_active Application Discontinuation
-
2007
- 2007-04-12 IL IL182541A patent/IL182541A/en active IP Right Grant
- 2007-04-30 ZA ZA200703486A patent/ZA200703486B/en unknown
- 2007-06-05 NO NO20072864A patent/NO338158B1/no unknown
-
2010
- 2010-11-24 US US12/953,691 patent/US8309591B2/en active Active
-
2012
- 2012-10-23 HR HRP20120856TT patent/HRP20120856T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1811995T3 (pl) | 2012-12-31 |
| PT1811995E (pt) | 2012-08-03 |
| NZ554521A (en) | 2010-09-30 |
| BRPI0517719B1 (pt) | 2018-11-06 |
| SI1811995T1 (sl) | 2012-10-30 |
| NO20072864L (no) | 2007-06-05 |
| US20110071203A1 (en) | 2011-03-24 |
| MX2007005238A (es) | 2007-07-09 |
| ZA200703486B (en) | 2008-06-25 |
| CA2583876A1 (en) | 2006-05-11 |
| US20070299121A1 (en) | 2007-12-27 |
| US8309591B2 (en) | 2012-11-13 |
| IL182541A (en) | 2011-02-28 |
| CA2583876C (en) | 2012-05-29 |
| RS52504B (en) | 2013-04-30 |
| AU2005300451B2 (en) | 2011-01-20 |
| WO2006048501A1 (en) | 2006-05-11 |
| AU2005300451A1 (en) | 2006-05-11 |
| JP2008519012A (ja) | 2008-06-05 |
| EP1811995B1 (en) | 2012-07-25 |
| EP1811995A1 (en) | 2007-08-01 |
| BRPI0517719A (pt) | 2008-10-21 |
| KR20070085284A (ko) | 2007-08-27 |
| AR054987A1 (es) | 2007-08-01 |
| US7863311B2 (en) | 2011-01-04 |
| FI20041425A0 (fi) | 2004-11-05 |
| DK1811995T3 (da) | 2012-08-20 |
| KR101257672B1 (ko) | 2013-04-24 |
| JP4996472B2 (ja) | 2012-08-08 |
| IL182541A0 (en) | 2007-09-20 |
| ES2388442T3 (es) | 2012-10-15 |
| NO338158B1 (no) | 2016-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120856T1 (hr) | Transmukozni veterinarski pripravak koji sadrži detomidin | |
| RU2010123282A (ru) | Твердая лекарственная форма с быстрым высвобождением активного вещества, ее получение и применение | |
| JP2016175936A5 (hr) | ||
| JP2010138198A (ja) | 医薬活性剤を含有する速溶解性口腔消耗性フィルム | |
| RU2008124805A (ru) | Фармацевтические композиции, содержащие бупренорфин | |
| DK2906213T3 (en) | VETERINARY PROCEDURE FOR RELIEFING NOISE SENSITIVITY | |
| TW200533362A (en) | Use of meloxicam for the treatment of respiratory diseases in pig | |
| JP7065871B2 (ja) | イヌの分離不安症の治療における使用のためのデクスメデトミジンまたはメデトミジン | |
| MEP10808A (en) | Solid drug for oral use | |
| CN101180045A (zh) | 非甾类抗炎药物与α-2-δ配体的协同组合 | |
| BRPI0311511B1 (pt) | "preparações farmacêuticas líquidas, e sua aplicação". | |
| KR20040074999A (ko) | 케토프로펜을 함유하는 음료 제제 및 동물군에서 열병,염증 및/또는 통증을 수반하는 질환의 동시 치료에서 이의용도 | |
| HRP20020181B1 (hr) | Farmaceutski pripravci koji sadrže derivat benzamida kao aktivan sastojak | |
| ES2296820T3 (es) | Nuevos usos de agonistas 5-ht1a y de inhibidores de reabsorcion de serotina combinadas. | |
| JP2009533413A5 (hr) | ||
| US9757374B2 (en) | Aripiprazole compositions and methods for its transdermal delivery | |
| ES2366109T3 (es) | Formulaciones antihelmínticas. | |
| KR20160110209A (ko) | 케라틴 조직의 진균감염증 치료를 위한 약제학적 조성물 | |
| WO2001045727A3 (en) | Stabilized veterinary compositions comprising more than one antiviral agent | |
| JP6703987B2 (ja) | 噴霧可能な鎮痛剤組成物 | |
| EA200601285A1 (ru) | Нераспадающаяся твёрдая композиция для перорального применения с высокой дозой растворимых в воде лекарственных средств | |
| ES2533624T3 (es) | Composición para prevenir y tratar patologías odontoestomatológicas de los animales | |
| JP5984923B2 (ja) | 速溶性アザペロン顆粒製剤 | |
| ES2550790T3 (es) | Agente terapéutico para el dolor producido por cáncer | |
| EP1242062A2 (en) | Anhydrous gel comprising nsaid for topical administration to the oral cavity |